Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation

Autor: Alla Zamyatina, Antonio Molinaro, Cristina Nativi, Alberto Fernández-Tejada, Ihsan Gursel, Aneesh Thakur, Carmen Alvarez-Dominguez, Siobhán McClean, Peter van der Ley, Artur Summerfield, Camillo Rosano, Dragomira Majhen, Virgil E.J.C. Schijns, Sveinbjörn Gizurarson, Žiga Jakopin, Rita Berisio

Publikováno v: Schijns, Virgil; Majhen, Dragomira; van der Ley, Peter; Thakur, Aneesh; Summerfield, Artur; Berisio, Rita; Nativi, Cristina; Fernández-Tejada, Alberto; Alvarez-Dominguez, Carmen; Gizurarson, Sveinbjörn; Zamyatina, Alla; Molinaro, Antonio; Rosano, Camillo; Jakopin, Žiga; Gursel, Ihsan; McClean, Siobhán (2021). Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics, 13(4) MDPI 10.3390/pharmaceutics13040501
Pharmaceutics
Pharmaceutics, Vol 13, Iss 501, p 501 (2021)
Schijns, V, Majhen, D, Van Der Ley, P, Thakur, A, Summerfield, A, Berisio, R, Nativi, C, Fernández-tejada, A, Álverez-dominguez, C, Gizurarson, S, Zamyatina, A, Molinaro, A, Rosano, C, Jakopin, Ž, Gursel, I & Mcclean, S 2021, ' Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation ', Pharmaceutics, vol. 13, no. 4, 501 . https://doi.org/10.3390/pharmaceutics13040501

Vaccines are the most effective medical intervention due to their continual success in preventing infections and improving mortality worldwide. Early vaccines were developed empirically however, rational design of vaccines can allow us to optimise th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ab37e2248edd84bf4a4d441bb02f43
https://boris.unibe.ch/157742/1/b157742.pdf

Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity

Autor: Ed C. Lavelle, Virgil E.J.C. Schijns

Publikováno v: European journal of immunology 50 (2020) 7
European journal of immunology, 50(7), 932-938
European Journal of Immunology

The recent outbreak of coronavirus disease 2019 (COVID‐19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses an enormous threat to global public health and economies. Human coronaviruses normally cause no or m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8635750ec90d5b434df8f0c57ae97efa
https://research.wur.nl/en/publications/prevention-and-treatment-of-covid-19-disease-by-controlled-modula

Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines

Autor: Marius Strioga, Neringa Dobrovolskienė, Vita Pašukonienė, E. Mišeikytė-Kaubrienė, Živilė Gudlevičienė, Agata Mlynska, Werner Lubitz, Pavol Kudela, Virgil E.J.C. Schijns, Jan Aleksander Kraśko, Karolina Žilionytė, Adas Darinskas

Publikováno v: Vaccine, 36(29), 4171-4180
Vaccine 36 (2018) 29

Cancer immunotherapy with dendritic cell (DC)-based vaccines has been used to treat various malignancies for more than two decades, however generally showed a limited clinical success. Among various factors responsible for their modest clinical activ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0713f84a1810d08f50ebda8a2d1f6304
https://research.wur.nl/en/publications/tumor-lysate-loaded-bacterial-ghosts-as-a-tool-for-optimized-prod

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

Autor: Virgil E.J.C. Schijns, Chrystel Pretto, Florence M. Hofman, Peter Hantos, Thomas C. Chen, Daniela A. Bota, Apostolos Stathopoulos, Philippe Glorieux, Laurent Devillers, Denis Pierre, Pascal Mespouille

Publikováno v: Vaccine, vol 33, iss 23
Schijns, VEJC; Pretto, C; Devillers, L; Pierre, D; Hofman, FM; Chen, TC; et al.(2015). First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo-and auto-immune tumor reactivity. Vaccine. doi: 10.1016/j.vaccine.2015.03.095. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/0pj6d78n
Vaccine, 33(23), 2690-2696
Schijns, VEJC; Pretto, C; Devillers, L; Pierre, D; Hofman, FM; Chen, TC; et al.(2015). First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo-and auto-immune tumor reactivity. Vaccine, 33(23), 2690-2696. doi: 10.1016/j.vaccine.2015.03.095. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/68b3t6dt
Vaccine 33 (2015) 23

© 2015 The Authors. Glioblastoma multiforme (GBM) patients have a poor prognosis. After tumor recurrence statistics suggest an imminent death within 1-4.5 months. Supportive preclinical data, from a rat model, provided the rational for a prototype c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3dddcb63d3d8b25f58438d883bc6eac
https://doi.org/10.1016/j.vaccine.2015.03.095

Therapeutic dendritic cell-based cancer vaccines: the state of art

Autor: Neringa Dobrovolskiene, Daniel J. Powell, Marius Strioga, Virgil E.J.C. Schijns, Thomas Felzmann, Miroslava Matuskova, Valerijus Ostapenko, Jaroslav Michálek

Publikováno v: Critical Reviews in Immunology, 33(6), 489-547
Critical Reviews in Immunology 33 (2013) 6

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to recognize cancer cells and uptake tumor antigens, they often have imp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb89abf3318ef29b35e024bfc5cc5308
https://doi.org/10.1615/critrevimmunol.2013008033